SAN DIEGO--(BUSINESS WIRE)--KFx announces the upcoming publications of results on its APPIANFx Femoral Implant for ACL Reconstruction at the upcoming ORS (Orthopedic Research Society 2012 Meeting) meeting February 4th-7th in San Francisco, CA.
“We believe this is a first ever report of a biomechanical test method that can accurately resolve and directly quantify the individual displacement components of ACL reconstructions under controlled cyclic and ultimate loading,” remarked an author, Mark Ehrensberger, Ph.D., Assistant Professor, Dept of Biomedical Engineering at Dept of Orthopaedic Surgery, State University of New York at Buffalo.
“This is a forward-thinking study combined with a comparative outcome versus the current market leader in ACL aperture fixation. The results encouraged us in our commercialization plans for market introduction of this exceptional technology platform for the ACL procedure,” remarked Tate Scott, president and CEO of KFx Medical Corporation.
“Our core technology platform enables us to provide implants for several distinct clinical procedures. As we anticipated, with the high adoption rate of our recently released APPIANFx Biceps Implant, customers have encouraged us to incorporate these significant core attributes into a femoral implant as well as other orthopedic procedures.”
The new APPIANFx line of implants from KFx reattach tissue to, and in, bone in shoulder, knee, foot and ankle procedures which combined exceed well over 1 million annual surgical procedures in the United States. Product offerings include those that directly place and secure tissue into bone both with and without the use of sutures.
About KFx Medical Corporation
Headquartered in Carlsbad, Calif., KFx Medical Corporation was founded in 2003 to develop products for tissue fixation in a variety of orthopedic surgical procedures performed on the shoulder, knee, foot, and ankle. KFx provides simple systems for orthopedic surgeons focused on sports medicine. The company is privately held — Investors include Alloy Ventures, Charter Life Sciences, Arboretum Ventures, Montreux Equity Partners, and MB Venture Partners.